Skip to main content
    S

    Scynexis Inc (SCYX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.99
    -0.04 (-0.99%)

    Market Cap: $39.70M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    +4.14%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.72
    Range$-0.79 - $-0.65
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.56-28.6%
    60d ago$-0.51-42.1%
    30d ago$-0.51-42.1%
    7d ago$-0.51-42.1%
    Current$-0.72
    Revenue Consensus
    $98000
    Range$0 - $294000
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.56
    Range$-1.68 - $-1.44
    2 analysts
    Revenue Consensus
    $364170
    Range$-20330 - $748670
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.56---
    Sep 26EST
    		-$-0.72---
    Jun 26
    Reported Aug 10
    		$-0.32$-0.40+20.00%Beat+71.4%
    Mar 26
    Reported May 11
    		$-3.36$-0.99-239.39%Miss-1876.5%
    Dec 25
    Reported Mar 4
    		$2.00$1.01+97.37%Beat+2322.2%
    Sep 25
    Reported Nov 5
    		$-0.17$-0.21+19.05%Beat+64.6%
    Jun 25
    Reported Aug 14
    		$-1.12$-1.52+26.32%Beat+53.3%
    Mar 25
    Reported May 16
    		$-0.17$-0.23+26.09%Beat-312.5%
    Dec 24
    Reported Mar 12
    		$-0.09N/A+59.09%Beat+76.9%
    Sep 24
    Reported Nov 5
    		$-0.48$-0.78+38.46%Beat-50.0%
    Jun 24
    Reported Aug 7
    		$-2.40$-1.62-48.15%Miss-112.2%
    Mar 24
    Reported May 8
    		$0.08N/A+105.16%Beat+111.3%
    Dec 23
    Reported Mar 29
    		$-0.39$-0.20-95.00%Miss+83.2%
    Sep 23
    Reported Nov 12
    		$-0.32N/A+72.65%Beat+93.5%
    Jun 23
    Reported Aug 13
    		$19.68$11.62+69.36%Beat+893.5%
    Mar 23
    Reported May 11
    		$-0.71$-0.28-153.57%Miss+47.8%
    Dec 22
    Reported Mar 31
    		$-2.32$-3.25+28.62%Beat-121.0%
    Sep 22
    Reported Nov 9
    		$-4.96$-3.94-25.89%Miss+10.8%
    Jun 22
    Reported Aug 15
    		$-2.48$-4.72+47.46%Beat-616.7%
    Mar 22
    Reported May 12
    		$-1.36N/A+78.06%Beat-126.7%
    Dec 21
    Reported Mar 29
    		$-1.05$-0.77-36.36%Miss+70.3%
    Sep 21
    Reported Nov 10
    		$-5.56$-5.64+1.42%Beat+39.0%
    Jun 21
    Reported Aug 16
    		$0.48N/A+110.17%Beat+111.3%
    Mar 21
    Reported May 17
    		$-0.60N/A+89.19%Beat+89.3%
    Dec 20
    Reported Mar 29
    		$-3.53$-0.81-335.80%Miss-60.5%
    Sep 20
    Reported Nov 6
    		$-9.12$-8.56-6.54%Miss+18.6%
    Jun 20
    Reported Aug 10
    		$-4.24N/A+55.46%Beat+65.4%
    Mar 20
    Reported May 11
    		$-5.60N/A+53.33%Beat+84.4%
    Dec 19
    Reported Mar 11
    		$-2.20$-1.90-15.79%Miss-120.0%
    Sep 19
    Reported Nov 12
    		$-11.20$-18.08+38.05%Beat-0.1%
    Jun 19
    Reported Aug 7
    		$-12.27$-15.60+21.35%Beat+33.3%
    Mar 19
    Reported May 8
    		$-35.84$-15.31-134.10%Miss-273.3%
    Dec 18
    Reported Mar 14
    		$-1.00$-1.42+29.58%Beat+63.0%
    Sep 18
    Reported Nov 13
    		$-11.19$-13.60+17.72%Beat+54.9%
    Jun 18
    Reported Aug 9
    		$-18.40$-14.06-30.87%Miss-43.7%
    Mar 18
    Reported May 8
    		$-9.60$-15.20+36.84%Beat+52.0%
    Dec 17
    Reported Mar 13
    		$-2.70$-2.85+5.26%Beat-440.0%
    Sep 17
    Reported Nov 7
    		$-24.80$-24.00-3.33%Miss-
    Jun 17
    Reported Aug 8
    		$-12.80$-22.40+42.86%Beat-
    Mar 17
    Reported May 8
    		$-20.00$-22.40+10.71%Beat-
    Dec 16
    Reported Mar 13
    		$-0.50N/A+86.74%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.16EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-53.30%Operating Margin-3309.00%
    ROE-18.40%ROIC-14.46%
    Financial Health
    Debt/Equity0.01xInterest Coverage11.32x
    Current Ratio9.65xQuick Ratio9.65x
    Trading Statistics
    Beta1.06Avg Volume512.58K
    52-Week High$9.1252-Week Low$3.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.64
    SMA 20$4.57
    SMA 50$4.90
    SMA 200$5.63
    EMA 10$4.42
    EMA 20$4.58
    EMA 50$4.74
    EMA 200$5.41

    MACD

    Line: -0.16Signal: -0.08Hist: -0.09

    ADX

    ADX: 20.2+DI: 20.1-DI: 23.9

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down100.0
    PSAR$5.34

    Bollinger Bands

    Upper Band$5.34
    Lower Band$3.80
    %B Position3366%(Upper)
    Band Width0.12

    RSI (14-Day)

    Neutral
    36.5

    Momentum Oscillators

    Stoch %K3.5
    Stoch %D8.6
    Williams %R-95.6
    ROC (10d)-14.4%
    Momentum-0.67
    CCI (20d)-137.0
    MFI (14d)82.1

    Volatility Measures

    ATR (14d)$0.38(9.6%)
    StdDev (20d)0.38
    Hist Vol88.4%(High)

    Volume Flow

    VWAP$4.00
    OBV21.2M
    AD Line20.8B
    CMF (20d)-0.364

    Volume Metrics

    Avg Vol (20d)558.2K
    Vol Ratio0.1x(Low)
    VWMA (20d)$4.66

    Pivot Points

    R3$4.27
    R2$4.21
    R1$4.12
    Pivot Point$4.06
    S1$3.97
    S2$3.91
    S3$3.82

    Advanced Oscillators

    TSI-12.02
    Ultimate Osc28.3
    KST-57.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$235,000$0$18.65M$334,000$1.36M$257,000$977,000$660,000$736,000$1.37M$5.80M$1.76M
    Cost of Revenue$0$0N/A$0$0$0$0$0$0$0$15.20M$0
    Gross Profit$235,000$0$18.65M$334,000$1.36M$257,000$977,000$660,000$736,000$1.37M$-9,402,000$1.76M
    Operating Expenses$8.01M$16.94M$8.14M$8.74M$10.93M$8.87M$9.03M$10.98M$9.97M$10.88M$13.66M$11.86M
    R&D$3.89M$12.35M$4.55M$5.45M$7.14M$5.14M$4.31M$8.07M$6.81M$7.21M$10.59M$6.47M
    SG&A$4.12M$4.59M$3.60M$3.29M$3.78M$3.73M$4.72M$2.91M$3.17M$3.67M$3.59M$5.01M
    Operating Income$-7,775,000$-16,939,000$10.50M$-8,405,000$-9,561,000$-8,610,000$-8,052,000$-10,320,000$-9,237,000$-9,508,000$-23,065,000$-10,098,000
    Interest Income$685,000$535,000$437,000$454,000$510,000$776,000$861,000$1.02M$1.13M$1.28M$1.37M$1.26M
    Interest Expense$0$0$0$0$0$485,000$676,000$654,000$618,000$606,000$603,000$572,000
    Income Before Tax$7.40M$0$12.26M$-8,591,000$-6,885,000$0$-4,418,000$-3,203,000$-14,458,000$942,000$-19,448,000$-1,757,000
    Income Tax Expense$0$0$0$0$0$0$15,000$-395,000$0$531,000$138,000$0
    Net Income$7.40M$-21,299,000$12.26M$-8,591,000$-6,885,000$-5,391,000$-4,433,000$-2,808,000$-14,458,000$411,000$-19,586,000$-1,757,000
    EBITDA$6.64M$-21,875,000$11.76M$-9,143,000$-7,510,000$-5,569,000$-4,382,000$-3,605,000$-14,917,000$416,000$-20,343,000$-2,743,000
    EBIT$6.71M$-21,834,000$11.82M$-9,045,000$-7,395,000$-5,682,000$-4,603,000$-3,569,000$-14,970,000$268,000$-20,212,000$-2,448,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SCYX

    News

    SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026

    SCYNEXIS has completed a Phase 1 study for SCY-770, an oral AMPK activator, demonstrating a favorable safety and tolerability profile in healthy participants. These positive results support the planned initiation...

    Quiver Quantitative•10/6/26•Bullish

    SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026

    SCYNEXIS, Inc. announced positive Phase 1 results for its oral AMPK activator, SCY-770, showing a favorable safety and tolerability profile in healthy participants. These results support the planned Phase 2...

    Quiver Quantitative•10/6/26•Bullish

    Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247

    Scynexis, Inc. has secured a contract with the Biomedical Advanced Research and Development Authority (BARDA) for up to $214 million in non-dilutive funding. This funding will advance their second-generation fungerp...

    AllSci•9/30/26•Bullish

    SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247

    SCYNEXIS Inc. (NASDAQ: SCYX) has secured a contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to $214 million. This non-dilutive funding will advance SCY-247...

    citybiz•9/29/26•Neutral

    SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ

    This page provides live stock quotes and charts for SCYNEXIS Inc. (SCYX) on NASDAQ, showing a current price of $4.55 with a slight decrease. It notes that there is no analyst rating or earnings information available...

    Timothy Sykes•9/29/26•Neutral

    SCYX Valuation and Fair Value

    P/E
    -2.2x
    Forward P/E
    1.9x
    PEG
    0.0x
    P/B
    0.7x
    See GNG's fair value

    SCYX Profitability: Margins, ROIC and FCF

    Operating margin
    -3309.0%
    Net margin
    -53.3%
    ROIC
    -14.5%
    ROE
    -18.4%
    FCF margin
    -69.3%

    SCYX Competitors

    CompanyTicker
    Grace Therapeutics, Inc.GRCE
    CVRx IncCVRX
    Nano X Imaging LtdNNOX
    FibroGen IncFGEN
    Instil Bio Inc.TIL
    Cosmos Health Inc.COSM
    Precipio IncPRPO
    Nephros IncNEPH

    Sector: Healthcare

    SCYX Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    2
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SCYX Bull Case vs Bear Case

    Bull case

    • SCYX beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • SCYX has a -53.3% net profit margin.
    • SCYX's quarterly revenue changed -82.8% year over year.

    SCYX Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    5.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.72
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About SCYX

    Does SCYX pay dividends?

    Scynexis Inc (SCYX) does not currently pay a regular dividend.

    What is SCYX's market cap?

    Scynexis Inc (SCYX) has a market capitalization of $39.70M with a current stock price of $3.99.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In